News FDA panel backs Ardelyx CKD drug, despite agency concerns While the FDA seems to remain sceptical about the clinical benefits of Ardelyx's chronic kidney disease (CKD) therapy Xphozah – having
R&D Reuters Pharma USA 2024 – Meruno Perugini Innovation in pharma comes in many forms, but at the end of the day what the industry cares about is results.
Digital Fixing clinical trial data management It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.